Bluejay Diagnostics (NASDAQ:BJDX) Issues Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) issued its quarterly earnings results on Wednesday. The company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88, FiscalAI reports.

Bluejay Diagnostics Stock Down 1.9%

BJDX stock traded down $0.02 during midday trading on Wednesday, reaching $1.05. 310,898 shares of the company’s stock traded hands, compared to its average volume of 2,516,201. The firm’s fifty day moving average price is $2.31 and its 200-day moving average price is $2.24. Bluejay Diagnostics has a 52 week low of $0.83 and a 52 week high of $16.68. The company has a market cap of $1.08 million, a price-to-earnings ratio of -0.09 and a beta of 0.89.

Insider Buying and Selling at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt acquired 64,047 shares of Bluejay Diagnostics stock in a transaction dated Thursday, July 9th. The stock was purchased at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the acquisition, the insider directly owned 126,993 shares of the company’s stock, valued at $191,759.43. This represents a 101.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Analyst Ratings Changes

BJDX has been the subject of several recent analyst reports. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Bluejay Diagnostics has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.